Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH1110760852
Mon, 19.12.2022
PolyPeptide
Media Release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide signs significant commercial agreement
Baar, 19 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the signing of a significant commercial a [ … ]
Fri, 02.12.2022
PolyPeptide
Media Release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide provides market update
Baar, 2 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today provided a market update.
Audio webcast scheduled for today at 09.30 am CET.
Several op [ … ]
Fri, 02.12.2022
PolyPeptide
Media Release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide provides market update
Baar, 2 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today provided a market update.
Audio webcast scheduled for today at 09.30 am CET.
Several op [ … ]
Fri, 19.08.2022
PolyPeptide Group
Media Release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide with encouraging progress within custom projects pipeline – however with lower profitability in the first half of 2022
Baar, 19 August 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligo-nucleotide-based active phar [ … ]
Fri, 19.08.2022
PolyPeptide Group
Media Release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide with encouraging progress within custom projects pipeline – however with lower profitability in the first half of 2022
Baar, 19 August 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligo-nucleotide-based active phar [ … ]
Tue, 12.07.2022
PolyPeptide Group
Media Release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide provides market update
Baar, 12 July 2022 – PolyPeptide Group AG (PolyPeptide), a global leader in peptide and oligonucleotide development and manufacturing, today provides a market update. While investing to implement its growth strategy [ … ]
Tue, 12.07.2022
PolyPeptide Group
Media Release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide provides market update
Baar, 12 July 2022 – PolyPeptide Group AG (PolyPeptide), a global leader in peptide and oligonucleotide development and manufacturing, today provides a market update. While investing to implement its growth strategy [ … ]
Tue, 15.03.2022
PolyPeptide Group
Media Release - ad hoc announcement pursuant to Art. 53 LR
PolyPeptide achieves strong profitable growth in 2021
Zug, 15 March 2022 - PolyPeptide Group AG (SIX: PPGN), a global leader in peptide custom development and manufacturing, today announced its results for the financial year 2021:
- Revenue growth of 26.5% year-over-year to EUR 282.1 mil [ … ]
Wed, 01.12.2021
PolyPeptide Group
Media Release - ad hoc announcement pursuant to Art. 53 LR
PolyPeptide Group appoints Neil Thompson as Director Global Sales and Marketing and member of the Executive Committee, succeeding Jan Christensen
Zug, December 1, 2021 - PolyPeptide Group AG, a global leader in peptide development and manufacturing, today announced the appointment of Neil [ … ]
Wed, 10.11.2021
PolyPeptide Group
Media Release
Ad hoc announcement pursuant to Art. 53 LR
Results of Accelerated Bookbuild Offering of 1,500,000 Existing Shares in PolyPeptide Group AG
Zug, 10 November 2021 - PolyPeptide Group AG ("PolyPeptide") has been informed that Draupnir Holding B.V. ("Draupnir"), which held 60.0% of PolyPeptide's share capital as of close of trading on S [ … ]